Goldman Sachs’s Y-mAbs Therapeutics YMAB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-212,751
| Closed | -$960K | – | 6692 |
|
|
2025
Q2 | $960K | Buy |
212,751
+10,975
| +5% | +$49.3K | ﹤0.01% | 4739 |
|
|
2025
Q1 | $894K | Sell |
201,776
-17,399
| -8% | -$101K | ﹤0.01% | 4769 |
|
|
2024
Q4 | $1.72M | Sell |
219,175
-3,425
| -2% | -$41.7K | ﹤0.01% | 4413 |
|
|
2024
Q3 | $2.93M | Buy |
222,600
+83,861
| +60% | +$1.06M | ﹤0.01% | 3814 |
|
|
2024
Q2 | $1.68M | Sell |
138,739
-226,797
| -62% | -$3.06M | ﹤0.01% | 4051 |
|
|
2024
Q1 | $5.94M | Sell |
365,536
-32,415
| -8% | -$437K | ﹤0.01% | 2939 |
|
|
2023
Q4 | $2.71M | Buy |
397,951
+8,604
| +2% | +$49.8K | ﹤0.01% | 3682 |
|
|
2023
Q3 | $2.12M | Sell |
389,347
-13,304
| -3% | -$77.5K | ﹤0.01% | 3726 |
|
|
2023
Q2 | $2.73M | Buy |
402,651
+211,860
| +111% | +$1.59M | ﹤0.01% | 3628 |
|
|
2023
Q1 | $956K | Sell |
190,791
-126,061
| -40% | -$515K | ﹤0.01% | 4408 |
|
|
2022
Q4 | $1.55M | Buy |
316,852
+133,775
| +73% | +$972K | ﹤0.01% | 4126 |
|
|
2022
Q3 | $2.64M | Buy |
183,077
+31,351
| +21% | +$519K | ﹤0.01% | 3726 |
|
|
2022
Q2 | $2.3M | Buy |
151,726
+25,615
| +20% | +$299K | ﹤0.01% | 3926 |
|
|
2022
Q1 | $1.5M | Sell |
126,111
-91,250
| -42% | -$937K | ﹤0.01% | 4487 |
|
|
2021
Q4 | $3.52M | Sell |
217,361
-595,994
| -73% | -$12.7M | ﹤0.01% | 3748 |
|
|
2021
Q3 | $23.2M | Sell |
813,355
-7,127
| -0.9% | -$225K | ﹤0.01% | 1930 |
|
|
2021
Q2 | $27.7M | Buy |
820,482
+2,633
| +0.3% | +$84.5K | 0.01% | 1758 |
|
|
2021
Q1 | $24.7M | Sell |
817,849
-43,589
| -5% | -$1.79M | 0.01% | 1768 |
|
|
2020
Q4 | $42.6M | Buy |
861,438
+135,321
| +19% | +$6.26M | 0.01% | 1252 |
|
|
2020
Q3 | $27.9M | Buy |
726,117
+146,239
| +25% | +$5.82M | 0.01% | 1474 |
|
|
2020
Q2 | $25.1M | Buy |
579,878
+85,237
| +17% | +$3.22M | 0.01% | 1490 |
|
|
2020
Q1 | $12.9M | Sell |
494,641
-82,205
| -14% | -$2.39M | ﹤0.01% | 1871 |
|
|
2019
Q4 | $18M | Buy |
576,846
+314,390
| +120% | +$9.3M | ﹤0.01% | 1955 |
|
|
2019
Q3 | $6.84M | Buy |
262,456
+36,589
| +16% | +$935K | ﹤0.01% | 2622 |
|
|
2019
Q2 | $5.17M | Buy |
225,867
+1,102
| +0.5% | +$25.3K | ﹤0.01% | 2819 |
|
|
2019
Q1 | $5.89M | Sell |
224,765
-13,013
| -5% | -$286K | ﹤0.01% | 2837 |
|
|
2018
Q4 | $4.84M | Sell |
237,778
-73,432
| -24% | -$1.69M | ﹤0.01% | 2912 |
|
|
2018
Q3 | $8.27M | Buy |
+311,210
| New | +$7.91M | ﹤0.01% | 2602 |
|
Other funds holding YMAB
Goldman Sachs's YMAB Position: Q3 2025 in Review
Goldman Sachs sold out of Y-mAbs Therapeutics (YMAB) in Q3 2025, closing a stake of 212,751 shares — an estimated $960K sold.
Goldman Sachs first reported a position in YMAB in Q3 2018 and held it in 28 quarters. The position peaked at $42.6M in Q4 2020. 2 funds tracked by Wall St. Rank hold YMAB as of Q3 2025.
- Goldman Sachs reported no remaining Y-mAbs Therapeutics position as of Q3 2025 after selling out during the quarter.
- Goldman Sachs sold 212,751 Y-mAbs Therapeutics shares in Q3 2025, an estimated $960K.
- Goldman Sachs first reported a position in Y-mAbs Therapeutics in Q3 2018 and held it in 28 quarters.
- Goldman Sachs's Y-mAbs Therapeutics position peaked at $42.6M in Q4 2020.
- 2 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q3 2025.
Based on Goldman Sachs's 13F filing for Q3 2025, filed 14 Nov 2025.